BTK Inhibitor ACP-196

An orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. (NCI Thesaurus)

YOU MAY ALSO LIKE

BTK Gene

This gene is involved in both signaling and B-cell development.

BTG2 wt Allele

Human BTG2 wild-type allele is located in the vicinity of 1q32 and is approximately 4 kb in length. This allele, which encodes…

BTG2 Gene

This gene is involved in the regulation of the G1/S transition of the cell cycle.

BTG1 wt Allele

Human BTG1 wild-type allele is located in the vicinity of 12q22 and is approximately 3 kb in length. This allele, which encodes…

BTG1 Gene

This gene is involved in the regulation of cell proliferation.

BTG Cell Cycle Regulation Pathway

BTG2 is found to be one of the immediate early genes up-regulated by neural growth factor (NGF) and epidermal growth factor…